Recent updates of precision therapy for gastric cancer: Towards optimal tailored management

Table 2 Ongoing clinical trials of target therapy in advanced gastric and esophagogastric junction adenocarcinoma

Trial identifier	Line of treatment	Phase of study	Treatment arms	Primary endpoint
Akt/mTOR inhibitors
NCT01613950[32]	Second/third	Ib	AUY922/BYL719	MTD
Immune checkpoints inhibitors
NCT02335411 (KEYNOTE-059)[91]	Third	II	Cohort 1: pembrolizumab monotherapy	ORR
			Cohort 2: pembrolizumab + 5-FU/cisplatin or capecitabine/cisplatin
NCT02370498 (KEYNOTE-061)[92]	Second	III	Pembrolizumab vs paclitaxel	PFS, OS
Multikinase inhibitors
NCT02015169[107]	Neoadjuvant	II	XELOX + lapatinib	R0 resection rate
NCT01913639[108]	First	II	FOLFOX + regorafenib	PFS

PFS: Progression free survival; OS: Overall survival; MTD: Maximum tolerated dose; 5-FU: 5-fluorouracin; ORR: Objective response rate; XELOX: Capecitabine/oxaliplatin; FOLFOX: 5-fluorouracil/leucovorin/oxaliplatin; mTOR: Mammalian target of rapamycin.